Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) shares hit a new 52-week low during trading on Friday . The stock traded as low as $9.05 and last traded at $9.60, with a volume of 228458 shares traded. The stock had previously closed at $9.44.
Astellas Pharma Stock Performance
The company has a quick ratio of 0.86, a current ratio of 1.10 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $17.37 billion, a PE ratio of 45.72 and a beta of 0.34. The firm’s 50-day moving average price is $9.93 and its two-hundred day moving average price is $10.99.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The company had revenue of $3.11 billion during the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. As a group, research analysts predict that Astellas Pharma Inc. will post 0.61 earnings per share for the current fiscal year.
Astellas Pharma Company Profile
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
- Five stocks we like better than Astellas Pharma
- How to Calculate Stock Profit
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Consumer Staples Stocks, Explained
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
